Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 8;11(4):475-483.
doi: 10.1093/nop/npae029. eCollection 2024 Aug.

Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study

Timothy A Gregory  1   2 , Stephanie R Knight  1 , Ashley E Aaroe  1 , Kaitlin N Highsmith  3 , Zachary C Janatpour  2 , Barbara J O'Brien  1 , Nazanin K Majd  1 , Monica E Loghin  1 , Chirag B Patel  1 , Shiao-Pei Weathers  1 , Vinay K Puduvalli  1 , Carlos Kamiya-Matsuoka  1
Affiliations

Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study

Timothy A Gregory et al. Neurooncol Pract. .

Abstract

Background: We observed rapid tumor progression following COVID-19 infection among patients with glioblastoma and sought to systematically characterize their disease course in a retrospective case-control study.

Methods: Using an institutional database, we retrospectively identified a series of COVID-19-positive glioblastoma cases and matched them by age and sex 1:2 to glioblastoma controls who had a negative COVID-19 test during their disease course. Demographic and clinical data were analyzed. Hyperprogression was defined using modified response evaluation criteria in solid tumors criteria. Time to progression and overall survival were estimated using the Kaplan-Meier method.

Results: Thirty-two glioblastoma cases with positive COVID-19 testing were matched to 64 glioblastoma controls with negative testing; age, sex, and molecular profiles did not differ between groups. Progression events occurred in 27 cases (84%) and 46 controls (72%). Of these, 14 cases (52%) presented with multifocal disease or leptomeningeal disease at progression compared with 10 controls (22%; P = .0082). Hyperprogression was identified in 13 cases (48%) but only 4 controls (9%; P = .0001). Cases had disease progression at a median of 35 days following COVID-19 testing, compared with 164 days for controls (P = .0001). Median survival from COVID-19 testing until death was 8.3 months for cases but 17 months for controls (P = .0016). Median overall survival from glioblastoma diagnosis was 20.7 months for cases and 24.6 months for controls (P = .672).

Conclusions: Patients with glioblastoma may have accelerated disease progression in the first 2 months after COVID-19 infection. Infected patients should be monitored vigilantly. Future investigations should explore tumor-immune microenvironment changes linking tumor progression and COVID-19.

Keywords: COVID-19; SARS-CoV-2; glioblastoma; glioma; progression.

PubMed Disclaimer

Conflict of interest statement

V.K.P. reports the following disclosures: Advisory board role and honoraria from Servier, Insightec, Novocure, and Orbus therapeutics, and equity in Moderna, Amarin and Gilead. The other authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
T1 + C MRI images from select glioblastoma cases at baseline before COVID-19 infection (top) and with notable progression 10–36 days after a positive COVID-19 test (bottom).
Figure 2.
Figure 2.
Time (days) from COVID-19 test to progression for A, all cases and controls; B, cases and controls who underwent COVID-19 testing during the first year (Y1) after diagnosis of glioblastoma; C, cases and controls who underwent COVID-19 testing during the second year (Y2) after diagnosis of glioblastoma; and D, cases and controls who underwent COVID-19 testing during the third year or beyond (Y3+) after diagnosis of glioblastoma.
Figure 3.
Figure 3.
Time (months) from COVID-19 test to death for A, all cases and controls; B, cases and controls who underwent COVID-19 testing during the first year (Y1) after diagnosis of glioblastoma; C, cases and controls who underwent COVID-19 testing during the second year (Y2) after diagnosis of glioblastoma; and D, cases and controls who underwent COVID-19 testing during the third year or beyond (Y3+) after diagnosis of glioblastoma.
Figure 4.
Figure 4.
Overall survival (months) of patients who had disease progression for A, all cases and controls; B, cases and controls who underwent COVID-19 testing during the first year after (Y1) diagnosis of glioblastoma; C, cases and controls who underwent COVID-19 testing during the second year (Y2) after diagnosis of glioblastoma; and D, cases and controls who underwent COVID-19 testing during the third year or beyond (Y3+) after diagnosis of glioblastoma.
See this image and copyright information in PMC

References

    1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Accessed March 15, 2023. https://coronavirus.jhu.edu/map.html
    1. Tabrizi S, Trippa L, Cagney D, et al.. A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. Neuro Oncol. 2020;22(7):918–927. - PMC - PubMed
    1. Mohile NA, Blakeley JO, Gatson NTN, et al.. Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neuro Oncol. 2020;22(7):912–917. - PMC - PubMed
    1. Aaroe A, Majd N, O’Brien B, et al.; D3CODE Team. COVD-30. A snapshot of the impact of COVID-19 on patients with nervous system tumors. Neuro-Oncology. 2020;22(Supplement_2):ii27–ii27.
    1. Mao L, Jin H, Wang M, et al.. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. - PMC - PubMed